The global market for GLP-1 drugs is on track to reach $133.92 billion by 2034, according to a new report from Polaris Market Research. The projected growth reflects how these therapies are moving beyond their original use in diabetes into obesity and cardiovascular disease treatment. The report analyzes the market across multiple dimensions, including drug class, route of administration, molecule type, indication, and region, providing a full view of the evolving setting. This shift in therapeutic use has been driven by accumulating clinical evidence and regulatory approvals that now recognize the broader metabolic benefits of GLP-1 receptor agonists.
Long-acting GLP-1 agonists dominated the market in 2025, the report notes, helped by less frequent dosing and a sustained therapeutic effect. These injectable formulations, typically administered once weekly, maintain steady drug levels in the body, which both improves glycemic control and reduces the burden of frequent injections for patients. The convenience of fewer doses has made them a preferred choice among prescribers and patients alike. But oral formulations are expected to grow fastest through 2034, as patients look for non-injectable alternatives. The first oral GLP-1 drug was approved only in recent years, and ongoing development efforts are focused on improving bioavailability and patient adherence. Among molecule types, biologics are projected to post the strongest gains, driven by their extended half-life and precise targeting. Biologics are large-molecule drugs derived from living organisms, and their design allows for once-weekly or even less frequent administration while minimizing off-target effects, a critical advantage for chronic therapy.
Obesity already the largest segment by indication
By indication, obesity was the biggest segment in 2025. That’s supported by expanding regulatory approvals and growing clinical acceptance of GLP-1 drugs for weight management. The underlying disease burden remains substantial. The World Health Organization estimated roughly 830 million people had diabetes worldwide in 2022, with more than 95% classified as type 2. Separately, the WHO reported 2.5 billion adults were overweight globally in 2022, including 890 million living with obesity. These numbers give some sense of the potential patient pool. It’s not hard to see why drugmakers are pouring resources into this class of medications. The market isn’t just about diabetes anymore — it’s about a much broader set of metabolic conditions that affect hundreds of millions of people. The high prevalence of obesity and overweight, combined with the strong weight-loss efficacy demonstrated in clinical trials, has positioned GLP-1 drugs as a key therapeutic option in weight management. As regulatory agencies continue to approve these drugs for obesity, the addressable patient population expands further, encompassing not only those with diabetes but also individuals with obesity or overweight who have related comorbidities such as hypertension or dyslipidemia.
Related: China liver cancer cases seen reaching 264000 by 2034
Asia Pacific leads regional growth
Asia Pacific is projected to post the fastest regional growth through 2034, driven by rising rates of lifestyle-related disease and improving healthcare access. India alone recorded 101 million diabetes cases in a 2023 study by the Indian Council of Medical Research. China’s market is also expanding, supported by government investment in chronic disease management and broader access to newer treatments. The rapid urbanization and dietary changes across many Asian countries have led to increasing rates of type 2 diabetes and obesity, creating a large and growing patient population. At the same time, healthcare infrastructure improvements are enabling more people to receive diagnoses and access modern therapies. In China, national initiatives to combat non-communicable diseases include investments in screening programs and negotiations to lower the cost of innovative drugs, which is expected to accelerate uptake of GLP-1 therapies. The demographic profile of the region, with a large cohort of middle-aged adults at risk of metabolic conditions, further reinforces the long-term growth outlook.
High treatment costs and affordability remain the market’s primary constraint, the report notes. That’s a tension that’s likely to persist, even as the ageing population adds further long-term demand. The United Nations projects the number of people aged 65 and over will rise from 761 million in 2021 to 1.6 billion by 2050, which means more patients needing glycemic and cardiometabolic therapies for years to come. The financial burden of these drugs, which can be substantial without insurance coverage, limits access in many low- and middle-income countries and places pressure on healthcare systems. Drugmakers are exploring pricing strategies, patient assistance programs, and the development of more affordable formulations to address this constraint. Despite these challenges, the underlying demographic trends and the expanding therapeutic indications for GLP-1 drugs are expected to sustain robust market growth throughout the forecast period.